Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
Public ClinicalTrials.gov record NCT03078751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Study identification
- NCT ID
- NCT03078751
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- Adjuvant endocrine therapy Drug
- Placebo Drug
- Ribociclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2017
- Primary completion
- Mar 8, 2020
- Completion
- Mar 8, 2020
- Last update posted
- Oct 10, 2021
2017 – 2020
United States locations
- U.S. sites
- 33
- U.S. states
- 17
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates PC- HAL | Tucson | Arizona | 85704 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| CBCC Global Research | Bakersfield | California | 93309 | — |
| University of California - Los Angeles | Los Angeles | California | 90024 | — |
| Ventura County Hematology and Oncology | Oxnard | California | 93030 | — |
| TRIO - Torrance Health Association | Redondo Beach | California | 90277 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| Rocky Mountain Cancer Centers Regulatory | Denver | Colorado | 80218 | — |
| Eastern Connecticut Hematology and Oncology Associates | Norwich | Connecticut | 06360 | — |
| Florida Cancer Specialists South Region | Fort Myers | Florida | 33916 | — |
| Memorial Regional Hospital | Hollywood | Florida | 33021 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Florida Cancer Specialists - North Florida Cancer Specialist N | St. Petersburg | Florida | 33705 | — |
| Northside Hospital Central Research Dept. | Atlanta | Georgia | 30342 | — |
| Summit Cancer Care, PC | Savannah | Georgia | 31405 | — |
| Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Div. | Leawood | Kansas | 66209 | — |
| Maryland Oncology Hematology P A | Silver Spring | Maryland | 20904 | — |
| Saint Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| Saint Barnabas Medical Center 2nd Floor East Wing | Livingston | New Jersey | 07039 | — |
| Pro Health Care Associates | New Hyde Park | New York | 11042 | — |
| The Presbyterian Hospital | Charlotte | North Carolina | 28210 | — |
| Tennessee Oncology, PLLC | Chattanooga | Tennessee | 37404 | — |
| The West Clinic | Germantown | Tennessee | 38138 | — |
| SCRI - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology P A Texas Oncology - Houston | Dallas | Texas | 75251 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
| Cancer Care Network of South Texas | San Antonio | Texas | 78258 | — |
| Texas Oncology PA - Tyler | Tyler | Texas | 75702 | — |
| Fairfax Northern Virginia Hem/Onc | Fairfax | Virginia | 22031 | — |
| Multicare Institute for Research and Innovation | Tacoma | Washington | 98405 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| Wenatchee Valley Hospital and Clinics | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03078751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 10, 2021 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03078751 live on ClinicalTrials.gov.